David Shan, Executive Vice President and Chief ISC Officer at Becton Dickinson & Co (NYSE:BDX), recently sold 1,500 shares of the company's common stock. The shares were sold at a price of $220.25 each, totaling $330,375. Following this transaction, Shan retains ownership of 6,285 shares in the company.
The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which Shan adopted on September 5, 2024. These plans allow company insiders to set up a predetermined schedule for selling stocks, helping to avoid any potential accusations of insider trading. The transaction was executed on December 5, 2024, and was signed off by Donna Kalazdy, acting under power of attorney for Shan. InvestingPro subscribers can access detailed financial health metrics, showing BDX maintains a strong balance sheet with low price volatility (Beta: 0.42) and comprehensive Pro Research Reports that provide deep-dive analysis of the company's fundamentals.
In other recent news, Becton Dickinson (BD), a leading medical technology firm, reported notable financial results in its Fourth Quarter and Full-Year Fiscal 2024 Earnings Call. BD posted a Q4 revenue growth of 7.4% and a full-year organic revenue increase of 5%. The adjusted diluted earnings per share (EPS) also rose by 11.4%, reaching $13.14 for the full year. Despite challenges in China and the Bioscience-Pharma sector, the MedTech and Diagnostics segments grew by 5.9%, with BD Medical (TASE:PMCN)'s biologic drug delivery sales surpassing $1 billion.
In terms of future expectations, BD anticipates revenue between $21.9 billion and $22.1 billion for FY '25, with adjusted diluted EPS guidance of $14.25 to $14.60. The company also announced a $1 billion share repurchase plan and increased its dividend by 9.5%. On the other hand, BD expects a mid-single-digit decline in China due to value-based procurement pressures.
BD has also made strides in innovation, expecting growth from innovations in biologics and diagnostics, and the integration of the Advanced Patient Monitoring business. Management also mentioned a focus on R&D investment for the integration of Advanced Patient Monitoring, with funding allocated for fiscal year 2025. These are some of the recent developments for Becton Dickinson.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.